Showing results (261-270 of 271) with videos related to

Sort By:
Pageof 28
Clinical Genitourinary Cancer|August 29, 2014
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trialReuben J Broom, Victoria Hinder, Katrina Sharples, et al.
Neuro-Oncology Advances|August 2, 2026
Intensive multimodal ketogenic metabolic therapy in glioblastoma: A clinical trialMatthew C L Phillips, Ziad Thotathil, Nur Azri Bin Haji Mohd Yasin, et al.
British Journal of Urology|December 11, 1997
Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' Study. International Continence Society--Benign Prostatic HyperplasiaJ L Donovan, H E Kay, T J Peters, et al.
Plos One|December 19, 2013
From knock-out phenotype to three-dimensional structure of a promising antibiotic target from Streptococcus pneumoniaeCon Dogovski, Michael A Gorman, Natalia E Ketaren, et al.
Structure (London, England : 1993)|July 19, 2016
Structural Determinants Defining the Allosteric Inhibition of an Essential Antibiotic TargetTatiana P Soares da Costa, Sebastien Desbois, Con Dogovski, et al.
Molecular Genetics and Genomics : MGG|July 29, 2003
Molecular analysis of two cytochrome P450 monooxygenase genes required for paxilline biosynthesis in Penicillium paxilli, and effects of paxilline intermediates on mammalian maxi-K ion channelsL K McMillan, R L Carr, C A Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BMatteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
The Lancet. Oncology|July 22, 2017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialGeorgina V Long, Victoria Atkinson, Jonathan S Cebon, et al.
Interventional Pain Medicine|June 15, 2026
Observations from the RESET clinical trial: A post-hoc per protocol analysis of clinical outcomes with percutaneous 60-day medial branch PNS in chronic low back painSean Li, Zachary L McCormick, Denise D Lester, et al.
Pain Medicine (Malden, Mass.)|October 25, 2025
Comparison of Percutaneous 60-Day Peripheral Nerve Stimulation of the Lumbar Medial Branches to Usual Care with Standard Interventional Management for Chronic Low Back Pain-a Multicenter Pragmatic Randomized Controlled Trial (RESET)Zachary L McCormick, Denise D Lester, Michael J DePalma, et al.
Pageof 28